Abstract Number: 0943 • ACR Convergence 2022
Increased Prevalence of Thrombotic Events in Anti-Phospholipid Antibody-Positive SLE Patients on Estrogen-Containing Contraception
Background/Purpose: Women of child-bearing age with underlying rheumatic disease such as systemic lupus erythematous (SLE) with positive anti-phospholipid antibodies (aPL) are at an increased risk…Abstract Number: 0680 • ACR Convergence 2022
Association of Environmental Risk Factors with Antiphospholipid Antibodies and Thrombosis in 1199 International Patients Referred for Suspected Antiphospholipid Syndrome
Background/Purpose: Whether environmental risk factors induce antiphospholipid antibody (aPL) positivity and increase the risk of arterial thrombosis (AT) and venous thromboembolism (VTE) in aPL-positive patients…Abstract Number: 1066 • ACR Convergence 2022
Capillaroscopic Findings in Autoimmune Connective Tissue Diseases: Results from 20 Years of Experience in a Training Referral Center
Background/Purpose: Nailfold videocapillaroscopy (NVC) allows the safe and fast detection of different microvascular patterns in patients affected by autoimmune connective tissue diseases (CTDs). The prevalence of…Abstract Number: 0681 • ACR Convergence 2022
Antiphospholipid Antibodies and Incident Cardiovascular Events in a Diverse Population: Results from the Dallas Heart Study
Background/Purpose: While circulating antiphospholipid antibodies (aPL) are recognized as an important acquired risk factor for thrombotic events, the prevalence of aPL in the general population…Abstract Number: 1465 • ACR Convergence 2022
Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort
Background/Purpose: Antiphospholipid Antibody (aPL) are described in 11-40% of patients with SLE. Whether the presence of any of the aPLs or combinations thereof, can accurately…Abstract Number: 0682 • ACR Convergence 2022
Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up
Background/Purpose: To estimate the incidence rate of new thrombotic events in a large single-center prospective cohort of primary antiphospholipid syndrome (PAPS) patients after approximately 5.5…Abstract Number: 1466 • ACR Convergence 2022
Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
Background/Purpose: Cardiovascular diseases (CVDs) represent one of the most life-threatening conditions that can affect SLE patients. Assessing the potential CVD risk of these patients is…Abstract Number: 0683 • ACR Convergence 2022
ANA-positive versus ANA-negative Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases: Clinical and Serological Characteristics, Results from the APS ACTION Clinical Database and Repository
Background/Purpose: APS ACTION is an international Clinical Database and Repository of persistently antiphospholipid antibody (aPL)-positive subjects, collecting demographic, medical history, and aPL data.This study focused…Abstract Number: 1677 • ACR Convergence 2022
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…Abstract Number: 0684 • ACR Convergence 2022
Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)
Background/Purpose: The APS ACTION is a network collecting and analyzing data ofaPL positive patients recruited by international centers. Based on the assumption that triple aPL-positive…Abstract Number: 1689 • ACR Convergence 2022
Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
Background/Purpose: It has previously been reported that 6-gingerol, the most abundant phytochemical in ginger root, inhibits neutrophil phosphodiesterase activity and thereby counteracts neutrophil hyperactivity in…Abstract Number: 0685 • ACR Convergence 2022
The Association of Antiphospholipid Antibodies with Previous SARS-CoV-2 Infection Among Elective Knee Replacement Patients
Background/Purpose: Acute SARS-CoV-2 infection has been associated with antiphospholipid antibodies (aPL), though it is unclear if aPL contribute to the hypercoagulability seen with COVID19, or…Abstract Number: 1721 • ACR Convergence 2022
Protective Effects of the Natural Antioxidant Taxifolin in Models of Lupus and Antiphospholipid Syndrome
Background/Purpose: Taxifolin, also known as dihydroquercetin, is a bioactive flavonoid commonly found in apples, onions, French maritime bark, and milk thistle. Given its potent anti-inflammatory…Abstract Number: 0074 • ACR Convergence 2021
Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19
Background/Purpose: Critically ill patients with COVID-19 infection have a profound hypercoagulable state and can often develop thromboses in many different vascular beds. Given the presence…Abstract Number: 1501 • ACR Convergence 2021
Molecular Modelling Predicts Inhibition of Functional Effects of Anti-thrombin III on Factor Xa Mediated Complement Activation by Anti- Factor Xa IgG in SLE and APS
Background/Purpose: The significance of antibodies directed against activated Factor (FXa) and thrombin (Thr) found in ~40% of patients with Systemic Lupus Erythematosus (SLE) and/or Antiphospholipid…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 19
- Next Page »